Analyzing Dicerna Pharmaceuticals (DRNA) & Cotinga Pharmaceuticals (COTQF)

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Cotinga Pharmaceuticals (OTCMKTS:COTQF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Insider & Institutional Ownership

86.2% of Dicerna Pharmaceuticals shares are owned by institutional investors. 19.9% of Dicerna Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


This table compares Dicerna Pharmaceuticals and Cotinga Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Dicerna Pharmaceuticals -1,284.93% -52.17% -29.37%
Cotinga Pharmaceuticals N/A N/A -201.46%

Analyst Ratings

This is a breakdown of recent recommendations for Dicerna Pharmaceuticals and Cotinga Pharmaceuticals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dicerna Pharmaceuticals 0 0 8 0 3.00
Cotinga Pharmaceuticals 0 0 0 0 N/A

Dicerna Pharmaceuticals currently has a consensus target price of $22.57, indicating a potential upside of 86.54%. Given Dicerna Pharmaceuticals’ higher probable upside, analysts plainly believe Dicerna Pharmaceuticals is more favorable than Cotinga Pharmaceuticals.

Risk and Volatility

Dicerna Pharmaceuticals has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500. Comparatively, Cotinga Pharmaceuticals has a beta of 3.9, indicating that its stock price is 290% more volatile than the S&P 500.

Valuation & Earnings

This table compares Dicerna Pharmaceuticals and Cotinga Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dicerna Pharmaceuticals $6.18 million 133.77 -$88.85 million ($1.20) -10.08
Cotinga Pharmaceuticals N/A N/A -$3.82 million N/A N/A

Cotinga Pharmaceuticals has lower revenue, but higher earnings than Dicerna Pharmaceuticals.


Dicerna Pharmaceuticals beats Cotinga Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. The company has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Cotinga Pharmaceuticals Company Profile

Cotinga Pharmaceuticals Inc., a biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, a clinical stage oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. was founded in 1999 and is based in Boston, Massachusetts.

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with's FREE daily email newsletter.